Dr. Sofen is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
8930 S Sepulveda Blvd
Ste 114
Los Angeles, CA 90045Phone+1 310-337-7171Fax+1 310-337-1081
Summary
- Dr. Howard Sofen is a dermatologist in Los Angeles, CA and is affiliated with Ronald Reagan UCLA Medical Center. He received his medical degree from Drexel University College of Medicine and has been in practice 36 years. He is experienced in general dermatology, melanoma and cutaneous malignancies, and psoriasis; eczema.
Education & Training
- UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1982 - 1985
- University of Southern California/Los Angeles General Medical Center (USC/LA General)Internship, Internal Medicine, 1981 - 1982
- Drexel University College of MedicineClass of 1981
Certifications & Licensure
- CA State Medical License 1982 - 2025
- American Board of Dermatology Dermatology
Awards, Honors, & Recognition
- Fellow (FAAD) American Academy of Dermatology
Clinical Trials
- The Safety and Efficacy of Topical IDP-108 Versus Vehicle in Patients With Onychomycosis Start of enrollment: 2009 Nov 01
- Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris Start of enrollment: 2014 Mar 19
- A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
- Join now to see all
Publications & Presentations
PubMed
- 404 citationsEfficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, d...Diamant Thaçi, Eric L. Simpson, Lisa A. Beck, Thomas Bieber, Andrew Blauvelt
Lancet. 2016-01-02 - 222 citationsEfficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticos...Eric L. Simpson, Carsten Flohr, Lawrence F. Eichenfield, Thomas Bieber, Howard Sofen
Journal of the American Academy of Dermatology. 2018-05-01 - 12 citationsImpact of ixekizumab treatment on skin-related personal relationship difficulties in moderate-to-severe psoriasis patients: 12-week results from two Phase 3 trials.Lyn Guenther, Richard B. Warren, Jennifer Clay Cather, Howard Sofen, Yves Poulin
Journal of the European Academy of Dermatology and Venereology. 2017-11-01
Press Mentions
- Top 5 Small Cosmetic Dermatology SitesMay 4th, 2023
- Asana BioSciences to Present Additional Efficacy Data from Chronic Hand Eczema Phase 2b Trial of Oral SYK/JAK Inhibitor Gusacitinib at AAD VMX Late-Breaking SessionApril 22nd, 2021
- Improvements in Chronic Hand Eczema Seen with Oral Gusacitinib in Phase 2 StudyNovember 19th, 2020
- Join now to see all
Professional Memberships
- Fellow
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: